P/B
0,4
Vistagen Therapeutics
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
$10.8M
Market Cap • 9/14/2026
1998
(28 years)
Founded
2009
(17 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,6
EPS
—
Market Cap
Market Cap
10,8M
EV
-20,2M
EV/Revenue
-8,1
EV/EBITDA
0,2
EV/EBIT
0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-290,2%
Total Yield
-290,2%
Payout
0%
Retained Earnings
-490,3M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
2162,4%
Capex/Revenue
3,4%
Capex/D&A
40,8%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
2,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
11,6%
CAGR Op. Income 5Y
36,3%
CAGR Net Income 5Y
24,6%
CAGR EPS 5Y
-31,2%
CAGR OCF 5Y
32,2%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
3,1
Quick Ratio
2,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!